Valuation
- Market cap
- 74,263,000
- Revenue TTM
- $0
- Net income TTM
- $-28,750,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 233,300
- Avg volume
- 505,978
- Day's range
- $1.62 – $1.66
- Shares out
- 46,126,000
- Stochastic %K
- 21%
- Beta
- -0.63
- Analysts
- Strong Sell
- Price target
- $8.50
Company profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technol...
Show more
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 410 297 7793
- Website
- https://ostherapies.com
- Address
- 115 Pullman Crossing Road, Suite 103, Grasonville, United States
Latest news
No headlines yet.
